| Expression pattern: |
DN |
| Associated gene: |
DHX9, ADAR1, CDK1, cyclin B1 |
| Associated microRNA: |
- |
| Biological function: |
inhibits epithelial cell G2/M arrest, reduces profibrotic factor secretion, and mitigates extracellular matrix deposition and fibrosis in kidney and liver injury models |
| Molecular mechanism: |
circBNC2 encodes a translated protein (ctBNC2) that promotes CDK1/cyclin B1 complex formation and nuclear translocation; circBNC2 downregulation after injury is partially mediated by DHX9 upregulation (with ADAR1 facilitating DHX9 binding) |
| Biological pathway or process: |
cell cycle (inhibits); proliferation (promotes); fibrosis (inhibits) |
| Detected method: |
Q
B
H
S
|
| Validation methods: |
RNA-seq; RT-qPCR; divergent primers PCR; Sanger Sequencing; Northern Blot; RNase R Treatment; Actinomycin D / DRB Stability Assay; Nuclear-Cytoplasmic Fractionation; FISH / smFISH; ISH (In Situ Hybridization); Clinical Sample Validation; Transfection; RIP (RNA Immunoprecipitation); Luciferase Reporter Assay; Western Blot; Co-IP; In Vivo Animal Model; IHC (Immunohistochemistry); IF (Immunofluorescence); TUNEL; ELISA; Cell Cycle Assay |
| Clinical significance: |
Downregulation of circBNC2 is recapitulated in human IRI-induced chronic kidney disease and HBV-induced liver fibrosis, supporting clinical relevance as a potential therapeutic intervention target. |
| Description: |
circBNC2 is downregulated in kidney and liver fibrotic injury settings. It suppresses epithelial G2/M arrest and profibrotic factor secretion by encoding ctBNC2, which promotes CDK1/cyclin B1 complex formation and supports mitotic entry, thereby mitigating maladaptive repair and fibrosis. |
| Confidence score: |
0.8741 |